semaglutide results 3 months Month Steady Progress semaglutide 3 month results Told

Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease

Key Industry Developments: In October 2025 , Eli Lilly and Company achieved its fourth Phase III success with its oral GLP-1 receptor agonist, orforglipron, in type 2 diabetes trials

American College of Cardiology Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with T2D and Atherosclerotic Cardiovascular Disease In 2018, the American College of Cardiology (ACC) published an expert consensus decision pathway on the use of novel therapies, namely GLP-1 RAs and SGLT-2 inhibitors, to reduce cardiovascular risk in patients with T2D

If not properly removed, they oxidize on the skin and contribute to uneven tone, congestion, and dullness

Neither drug inhibits nor induces the other's metabolism

Sunal, and G